You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 17, 2025

CLINICAL TRIALS PROFILE FOR SEROQUEL XR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for SEROQUEL XR

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00060489 ↗ Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression Completed AstraZeneca Phase 3 2002-09-01 The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.
NCT00048802 ↗ Treatment and Outcome of Early Onset Bipolar Disorder Completed National Institute of Mental Health (NIMH) Phase 4 2002-08-01 This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder.
NCT00048802 ↗ Treatment and Outcome of Early Onset Bipolar Disorder Completed Northwell Health Phase 4 2002-08-01 This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder.
NCT00043849 ↗ Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) Completed National Institute on Aging (NIA) Phase 4 2002-07-01 The primary aim of this study is to determine the safety and efficacy of quetiapine (Seroquel) for the treatment of psychosis and/or agitation in patients with primary dementia complicated by coexistent parkinsonism, or patients with Parkinson's disease with dementia [PDD] who have episodes of agitation or psychosis. The secondary aim is to determine the safety and tolerability, particularly the influence on parkinsonism, of quetiapine when used to treat psychosis and/or agitation in patients with dementia complicated by coexistent parkinsonism.
NCT00034905 ↗ A Comparison of Seroquel vs. Risperidone in Schizophrenia Completed AstraZeneca Phase 4 2001-07-01 The purpose of this study is to show equal efficacy of both quetiapine and risperidone in subjects treated with study medication for up to 8 weeks.
NCT00044655 ↗ Switching Medication to Treat Schizophrenia Completed National Institute of Mental Health (NIMH) Phase 4 2001-07-01 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00044655 ↗ Switching Medication to Treat Schizophrenia Completed Icahn School of Medicine at Mount Sinai Phase 4 2001-07-01 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 7 of 7 entries

Clinical Trial Conditions for SEROQUEL XR

Condition Name

47321710005101520253035404550SchizophreniaBipolar DisorderMajor Depressive DisorderGeneralized Anxiety Disorder[disabled in preview]
Condition Name for SEROQUEL XR
Intervention Trials
Schizophrenia 47
Bipolar Disorder 32
Major Depressive Disorder 17
Generalized Anxiety Disorder 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

6251484300102030405060DiseaseSchizophreniaBipolar DisorderDepression[disabled in preview]
Condition MeSH for SEROQUEL XR
Intervention Trials
Disease 62
Schizophrenia 51
Bipolar Disorder 48
Depression 43
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SEROQUEL XR

Trials by Country

+
Trials by Country for SEROQUEL XR
Location Trials
United States 764
Canada 85
Italy 44
China 36
Korea, Republic of 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for SEROQUEL XR
Location Trials
New York 41
California 40
Texas 38
Ohio 34
Pennsylvania 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SEROQUEL XR

Clinical Trial Phase

39.8%33.3%25.8%001020304050607080Phase 4Phase 3Phase 2/Phase 3[disabled in preview]
Clinical Trial Phase for SEROQUEL XR
Clinical Trial Phase Trials
Phase 4 74
Phase 3 62
Phase 2/Phase 3 2
[disabled in preview] 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

76.6%10.9%6.8%5.7%0020406080100120140160CompletedTerminatedUnknown status[disabled in preview]
Clinical Trial Status for SEROQUEL XR
Clinical Trial Phase Trials
Completed 147
Terminated 21
Unknown status 13
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SEROQUEL XR

Sponsor Name

trials0102030405060708090100AstraZenecaNational Institute of Mental Health (NIMH)National Institute on Drug Abuse (NIDA)[disabled in preview]
Sponsor Name for SEROQUEL XR
Sponsor Trials
AstraZeneca 93
National Institute of Mental Health (NIMH) 7
National Institute on Drug Abuse (NIDA) 7
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

49.3%40.5%7.0%0020406080100120140OtherIndustryNIH[disabled in preview]
Sponsor Type for SEROQUEL XR
Sponsor Trials
Other 140
Industry 115
NIH 20
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

SEROQUEL XR: Clinical Trials, Market Analysis, and Projections

Introduction

SEROQUEL XR, the extended-release formulation of quetiapine fumarate, is a versatile antipsychotic medication used in the treatment of various psychiatric disorders, including schizophrenia, bipolar disorder, and major depressive disorder (MDD). Here, we will delve into the clinical trials, market analysis, and projections for this drug.

Clinical Trials and Efficacy

Schizophrenia and Bipolar Disorder

SEROQUEL XR has been extensively studied and approved for the treatment of schizophrenia and bipolar disorder. Clinical trials have demonstrated its efficacy in managing both manic and depressive episodes associated with bipolar I and II disorders. For example, the efficacy of SEROQUEL XR in manic or mixed episodes of bipolar I disorder was established in one 3-week trial and supported by two 12-week monotherapy trials and one 3-week adjunctive trial[4].

Major Depressive Disorder (MDD)

For MDD, SEROQUEL XR is indicated as an adjunctive therapy to antidepressants. The efficacy of SEROQUEL XR in this context was established in two 6-week trials in adults with MDD. However, the longer-term risks associated with its use in MDD, such as metabolic risks and the risk of tardive dyskinesia, have not been fully addressed and require ongoing monitoring[3][4].

Regulatory Updates

In 2009, AstraZeneca's application for SEROQUEL XR for the treatment of recurrent depressive episodes in adult patients with MDD was referred to the Committee for Medicinal Products for Human Use (CHMP) after being refused by the Netherlands Health Authority. Despite this, Health Canada approved SEROQUEL XR for the treatment of adult patients with MDD during the same period[1].

Safety Profile

Metabolic Risks

Post-marketing clinical trials have highlighted several safety concerns, including elevations in total cholesterol (predominantly LDL cholesterol), hyperglycemia, hyperlipidemia, and weight gain. These metabolic risks are significant and necessitate careful monitoring and risk-benefit analysis, especially in patients with MDD[3].

Other Safety Considerations

Additional safety concerns include the risk of tardive dyskinesia, a condition characterized by involuntary, repetitive body movements. This risk, along with the metabolic risks, underscores the need for cautious use and ongoing assessment of the drug's safety profile[3].

Market Analysis

Global Approval and Usage

SEROQUEL XR has been approved in numerous countries for various indications. It is approved in 53 countries for schizophrenia, 19 countries for bipolar mania, 20 countries for bipolar depression, and in two markets for MDD. The drug's global presence is significant, with approvals in 94 countries for schizophrenia and 92 countries for bipolar mania when including the immediate-release formulation, SEROQUEL[1].

Market Size and Competition

The market for antipsychotic medications, including SEROQUEL XR, is substantial. In the US, the sales of SEROQUEL XR extended-release tablets exceeded $1 billion in 2016. However, the market is expected to face significant changes due to the expiration of patents. Generic versions of SEROQUEL XR, approved by the FDA in 2017, are expected to erode the market share of the branded version. Companies like Lupin and Pharmadax have received approvals for generic versions, which will likely impact the market dynamics[2][5].

Generic Erosion

The expiration of patents for several antipsychotic medications, including SEROQUEL, is anticipated to lead to a highly genericized market. This trend is expected to limit sales growth in markets such as the 5EU (France, Germany, Italy, Spain, and the UK), where drug sales for schizophrenia reached $806.5 million in 2015. The introduction of generic versions will increase competition and reduce the market share of branded drugs like SEROQUEL XR[5].

Projections and Future Outlook

Market Forecast

Given the impending generic erosion, the market for SEROQUEL XR is projected to decline. The 5EU market, for instance, is expected to see reduced sales growth as generic versions become more prevalent. However, the drug's versatility and established efficacy in various psychiatric disorders may help it maintain some market presence, albeit at a reduced level[5].

Competitive Landscape

The competitive landscape for antipsychotic medications will become increasingly crowded with the entry of generic versions. Companies like Lupin and Pharmadax, which have already received FDA approvals for their generic versions of SEROQUEL XR, will play significant roles in this market. The ability of these generics to offer cost-effective alternatives will be a key factor in shaping the market[2].

Key Takeaways

  • Clinical Efficacy: SEROQUEL XR has demonstrated efficacy in treating schizophrenia, bipolar disorder, and as an adjunctive therapy for MDD.
  • Safety Concerns: The drug is associated with significant metabolic risks and other safety concerns that require careful monitoring.
  • Market Dynamics: The market is expected to face generic erosion, leading to reduced sales growth for the branded version.
  • Global Presence: SEROQUEL XR is approved in numerous countries for various indications, but its market share will be impacted by generic competition.
  • Future Outlook: The drug's market presence will likely decline due to generic competition, but it may maintain some presence due to its established efficacy.

FAQs

What is SEROQUEL XR used for?

SEROQUEL XR is used for the treatment of schizophrenia, bipolar disorder, and as an adjunctive therapy for major depressive disorder (MDD).

What are the common side effects of SEROQUEL XR?

Common side effects include elevations in total cholesterol, hyperglycemia, hyperlipidemia, weight gain, and the risk of tardive dyskinesia.

Has SEROQUEL XR been approved globally?

Yes, SEROQUEL XR has been approved in numerous countries for various indications, including 53 countries for schizophrenia and 19 countries for bipolar mania.

What impact will generic versions have on the market?

Generic versions of SEROQUEL XR are expected to erode the market share of the branded version, leading to reduced sales growth.

Are there any specific safety monitoring requirements for SEROQUEL XR?

Yes, due to the risk of metabolic side effects and tardive dyskinesia, careful monitoring and risk-benefit analysis are required.

Sources

  1. AstraZeneca Regulatory Update on Seroquel XR for the Treatment of Recurrent Depressive Episodes in Adult Patients with Major Depressive Disorder (MDD). AstraZeneca, 2009.
  2. FDA Approves Two New Seroquel XR Generics. GaBI Online, 2017.
  3. Seroquel XR Generic Name: quetiapine fumarate. FDA, 2009.
  4. Reference ID: 4928198. FDA, 2022.
  5. Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025. Business Wire, 2017.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.